C$0.01 trade: XCX.CN Greenrise Global Brands Inc. CNQ Market hours, watch liquidity
XCX.CN stock jumped to C$0.01 during market hours on 27 Feb 2026, up 100.00% from the prior close of C$0.005. The move occurred on effectively zero reported volume versus an average daily volume of 33,354 shares, highlighting extreme thin liquidity. This single-day gap drove the market cap to roughly C$516,554 and put the tiny healthcare issuer in focus for intraday traders and risk-aware investors. We review the drivers, valuation, technicals, Meyka AI grade, and a short trading checklist for market hours.
XCX.CN stock price action and volume
Greenrise Global Brands Inc. (XCX.CN) traded at C$0.01 on 27 Feb 2026 after opening at C$0.01, a one-day change of 100.00% versus the previous close of C$0.005. The reported intraday volume was 0 while the 50-day average sits near 33,354 shares, which signals illiquidity and the potential for outsized swings on small orders.
Fundamentals and valuation of Greenrise Global Brands Inc. (XCX.CN)
XCX.CN operates in Healthcare as a medical cannabis supplier to pharmacies in Germany and reports a market cap of C$516,554 and 51,655,400 shares outstanding. Trailing EPS is -0.03 with a negative PE of -0.33, book value per share is -0.09, and cash per share is 0.00. These metrics point to limited earnings and a fragile balance sheet versus sector norms where average PE is 13.92.
Technical snapshot and trading cues
Technical indicators show an RSI near 59.81 and ADX at 40.89, suggesting a strong short-term trend but mixed momentum. Price averages are low: 50-day around 0.006 and 200-day around 0.006. Key resistance sits near C$0.02 and support near the year low of C$0.005. Traders should note Bollinger upper band at 0.02, which frames near-term upside if liquidity arrives.
Meyka AI rates XCX.CN with a score out of 100
Meyka AI rates XCX.CN with a score out of 100: 64.88 (Grade B, Suggestion: HOLD). This grade factors S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a monthly target of C$0.02 and a 12-month model-level projection near C$0.022, implying about 120.00% upside versus the current C$0.01. Forecasts are model-based projections and not guarantees.
Risks and near-term catalysts for XCX.CN stock
The biggest risks are extreme illiquidity, negative earnings, weak book value, and limited operating cash flow. Catalyst events would include a trade volume uptick, a corporate update, or a new supply agreement in the EU. Analyst coverage and price target consensus are currently absent, increasing event risk for holders.
Trading note for market hours and sources
For market hours trading, use limit orders and small size to manage market impact given the low float and 50-day average volume of 33,354 shares. Watch for spikes in real-time volume and place stop limits. Company filings and the corporate site provide primary confirmation: Greenrise Global Brands website. For listed data and profile details see the issuer page on FinancialModelingPrep: FinancialModelingPrep profile.
Final Thoughts
XCX.CN stock is a high-risk, high-volatility microcap in the healthcare (medical cannabis) niche. The 100.00% intraday move to C$0.01 on 27 Feb 2026 reflects low liquidity and a shallow order book more than a change in fundamentals. Key ratios include EPS -0.03, PE -0.33, and a market cap near C$516,554, underscoring limited scale and fragile finances versus the healthcare sector. Meyka AI’s model projects a 12-month figure near C$0.022, implying roughly 120.00% upside from C$0.01, but this relies on improved volume and commercial progress. Traders should use strict risk controls, size positions small, and prefer limit orders during market hours. Investors seeking exposure should weigh the speculative nature, absence of analyst price targets, and the potential for binary outcomes tied to corporate developments. Remember, Meyka AI is an AI-powered market analysis platform, and forecasts are model-based and not guarantees.
FAQs
What caused the XCX.CN stock move on 27 Feb 2026?
The move to C$0.01 was driven by a thin order book and a small trade that doubled the price from C$0.005. Reported volume was zero but average volume is 33,354 shares, revealing fragile liquidity and price sensitivity.
What is the Meyka AI forecast for XCX.CN stock?
Meyka AI’s forecast model projects a monthly target of C$0.02 and a 12-month projection near C$0.022, implying about 120.00% upside versus the current C$0.01. Forecasts are model-based projections and not guarantees.
Is XCX.CN stock a buy for long-term investors?
XCX.CN is speculative with negative EPS, negative book value, and tiny market cap. Meyka AI grades it B (HOLD). Long-term investors should require clear operational progress and higher liquidity before adding exposure.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.